Health AI Central
Peer-Reviewed Publication
Ann Neurol2023;93(2):317-329.February 1, 2023Journal Article

Actigraphy Enables Home Screening of Rapid Eye Movement Behavior Disorder in Parkinson's Disease.

Flavio Raschellà1, Stefano Scafa2,3,4, Alessandro Puiatti4, Eduardo Martin Moraud2,3, Pietro-Luca Ratti5,6
1Onera Health, Eindhoven, the Netherlands.
2Defitech Center for Interventional Neurotherapies (.NeuroRestore), Lausanne University Hospital and Ecole Polytechnique Féderale de Lausanne (EPFL), Lausanne, Switzerland.
3Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
4Institute of Digital Technologies for Personalized Healthcare (MedITech), University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland.
5Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
6Al Centro del Sonno, Venice, Italy.
PubMed DOI

Abstract

OBJECTIVES: Rapid eye movement sleep behavior disorder (RBD) is a potentially harmful, often overlooked sleep disorder affecting up to 70% of Parkinson's disease patients. Current diagnosis relies on nocturnal video-polysomnography, which is an expensive and cumbersome examination requiring specific clinical expertise. Here, we explored the use of wrist actigraphy to enable automatic RBD diagnoses…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.